Cargando…

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients

BACKGROUND: Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and ky...

Descripción completa

Detalles Bibliográficos
Autores principales: Durastanti, Valentina, Lugaresi, Alessandra, Bramanti, Placido, Amato, Mariapia, Bellantonio, Paolo, De Luca, Giovanna, Picconi, Orietta, Fantozzi, Roberta, Locatelli, Laura, Solda', Annalisa, Sessa, Edoardo, Totaro, Rocco, Marino, Silvia, Zipoli, Valentina, Zorzon, Marino, Millefiorini, Enrico
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102623/
https://www.ncbi.nlm.nih.gov/pubmed/21501517
http://dx.doi.org/10.1186/1479-5876-9-42
_version_ 1782204396071813120
author Durastanti, Valentina
Lugaresi, Alessandra
Bramanti, Placido
Amato, Mariapia
Bellantonio, Paolo
De Luca, Giovanna
Picconi, Orietta
Fantozzi, Roberta
Locatelli, Laura
Solda', Annalisa
Sessa, Edoardo
Totaro, Rocco
Marino, Silvia
Zipoli, Valentina
Zorzon, Marino
Millefiorini, Enrico
author_facet Durastanti, Valentina
Lugaresi, Alessandra
Bramanti, Placido
Amato, Mariapia
Bellantonio, Paolo
De Luca, Giovanna
Picconi, Orietta
Fantozzi, Roberta
Locatelli, Laura
Solda', Annalisa
Sessa, Edoardo
Totaro, Rocco
Marino, Silvia
Zipoli, Valentina
Zorzon, Marino
Millefiorini, Enrico
author_sort Durastanti, Valentina
collection PubMed
description BACKGROUND: Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months. METHODS: RRMS patients (n = 101) received open-label IFNβ-1a 22 mcg (low dose, LD) or 44 mcg (high dose, HD) subcutaneously (sc), three times weekly for 24 months. Serum measurements of neopterin, kyn/trp ratio and neutralizing antibodies (NAbs) were obtained before treatment (i.e., at baseline) and 48 hours post-injection every 3 months thereafter. Clinical assessments were performed at baseline and every 6 months. Changes in biomarkers over time were compared between LD- and HD-group as well as between patients with/without relapses and with/without NAbs using Analysis of Variance and Mann-Whitney tests. RESULTS: Neopterin (p < 0.001) and kyn/trp ratio (p = 0.0013) values increased over time vs baseline in both treatment groups. Neopterin values were higher (p = 0.046) in the HD-compared to the LD-group at every time point with the exclusion of months 21 and 24 of therapy. Conversely, there were no differences between the two doses groups in the kyn/trp ratio with the exclusion of month 6 of therapy (p < 0.05). Neopterin levels were significantly reduced in NAb-positive patients starting from month 9 of therapy (p < 0.05); the same result was observed for kyn/trp ratio but only at month 9 (p = 0.02). Clinical status did not significantly affect neopterin production and tryptophan degradation. CONCLUSIONS: Although differences in serum markers concentration were found following IFNβ administration the clinical relevance of these findings needs to be confirmed with more detailed studies.
format Text
id pubmed-3102623
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31026232011-05-27 Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients Durastanti, Valentina Lugaresi, Alessandra Bramanti, Placido Amato, Mariapia Bellantonio, Paolo De Luca, Giovanna Picconi, Orietta Fantozzi, Roberta Locatelli, Laura Solda', Annalisa Sessa, Edoardo Totaro, Rocco Marino, Silvia Zipoli, Valentina Zorzon, Marino Millefiorini, Enrico J Transl Med Research BACKGROUND: Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months. METHODS: RRMS patients (n = 101) received open-label IFNβ-1a 22 mcg (low dose, LD) or 44 mcg (high dose, HD) subcutaneously (sc), three times weekly for 24 months. Serum measurements of neopterin, kyn/trp ratio and neutralizing antibodies (NAbs) were obtained before treatment (i.e., at baseline) and 48 hours post-injection every 3 months thereafter. Clinical assessments were performed at baseline and every 6 months. Changes in biomarkers over time were compared between LD- and HD-group as well as between patients with/without relapses and with/without NAbs using Analysis of Variance and Mann-Whitney tests. RESULTS: Neopterin (p < 0.001) and kyn/trp ratio (p = 0.0013) values increased over time vs baseline in both treatment groups. Neopterin values were higher (p = 0.046) in the HD-compared to the LD-group at every time point with the exclusion of months 21 and 24 of therapy. Conversely, there were no differences between the two doses groups in the kyn/trp ratio with the exclusion of month 6 of therapy (p < 0.05). Neopterin levels were significantly reduced in NAb-positive patients starting from month 9 of therapy (p < 0.05); the same result was observed for kyn/trp ratio but only at month 9 (p = 0.02). Clinical status did not significantly affect neopterin production and tryptophan degradation. CONCLUSIONS: Although differences in serum markers concentration were found following IFNβ administration the clinical relevance of these findings needs to be confirmed with more detailed studies. BioMed Central 2011-04-18 /pmc/articles/PMC3102623/ /pubmed/21501517 http://dx.doi.org/10.1186/1479-5876-9-42 Text en Copyright ©2011 Durastanti et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Durastanti, Valentina
Lugaresi, Alessandra
Bramanti, Placido
Amato, Mariapia
Bellantonio, Paolo
De Luca, Giovanna
Picconi, Orietta
Fantozzi, Roberta
Locatelli, Laura
Solda', Annalisa
Sessa, Edoardo
Totaro, Rocco
Marino, Silvia
Zipoli, Valentina
Zorzon, Marino
Millefiorini, Enrico
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
title Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
title_full Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
title_fullStr Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
title_full_unstemmed Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
title_short Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
title_sort neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102623/
https://www.ncbi.nlm.nih.gov/pubmed/21501517
http://dx.doi.org/10.1186/1479-5876-9-42
work_keys_str_mv AT durastantivalentina neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT lugaresialessandra neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT bramantiplacido neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT amatomariapia neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT bellantoniopaolo neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT delucagiovanna neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT picconiorietta neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT fantozziroberta neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT locatellilaura neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT soldaannalisa neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT sessaedoardo neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT totarorocco neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT marinosilvia neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT zipolivalentina neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT zorzonmarino neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients
AT millefiorinienrico neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients